Lilly reports full Q4 2024 financial results and provides 2025 guidance
Portfolio Pulse from
Eli Lilly reported a 45% increase in Q4 2024 revenue to $13.53 billion, driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue grew by 20% compared to Q4 2023.
February 06, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's Q4 2024 revenue increased by 45% to $13.53 billion, driven by strong performance from Mounjaro and Zepbound. Non-incretin revenue also saw a 20% growth compared to the previous year.
The significant revenue growth of 45% in Q4 2024, driven by key products Mounjaro and Zepbound, indicates strong market performance and demand. The 20% increase in non-incretin revenue further supports a positive outlook for Eli Lilly. This financial performance is likely to positively impact LLY's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100